Press Releases

Saudi Arabia’s Low-Cost Airline Chooses Mix Of A320neos & A321neos

Announcement Made At Future Aviation Forum In Saudi Capital Riyadh

Deliveries Scheduled To Begin In 2026 To Fuel Next Phase Of Expansion

RIYADH, Saudi Arabia--(BUSINESS WIRE)-- flyadeal, one of the youngest and fastest growing low-cost airlines in the Kingdom of Saudi Arabia and the Middle East, today announced a landmark order for 51 narrowbody Airbus aircraft to fuel the next phase of its... (continue reading...)

COLORADO SPRINGS, CO / ACCESSWIRE / May 22, 2024 / Fortitude Gold Corp. (OTCQB: FTCO) (the "Company") announced continued multiple wide, high-grade oxide gold drill intercepts from its West White Rock Springs target located on the northern portion of the East Camp Douglas property. Intercepts include 6.10 meters grading 3.47 grams per tonne (g/t) gold within 9.14 meters grading 2.45 g/t gold, 4.57 meters grading 4.62 g/t gold within 13.72 meters grading 1.83 g/t gold,... (continue reading...)

BEIJING, May 22, 2024 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX:2076), a leading online recruitment platform in China, today announced that it will hold an annual general meeting of the Company’s shareholders (the “AGM”) at 3 p.m. Beijing time on June 28, 2024 at 21/F, GrandyVic Building, Taiyanggong Middle Road, Chaoyang District, Beijing, China for the purposes of considering and, if thought fit, passing... (continue reading...)

CARMEL, Ind., May 22, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

... (continue reading...)

• Better Therapeutics assets include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia, and MASH.
• Initial efforts will focus on further development of AspyreRx to adapt it for the treatment of obesity and to benefit from Click’s AI-enabled platform as part of Click’s obesity digital therapeutic in development, CT-181; Click does not... (continue reading...)